Investigation Report on China Trastuzumab Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||296113|
|出版日期||內容資訊||英文 20 Pages
|中國的Trastuzumab市場調查 Investigation Report on China Trastuzumab Market, 2010-2019|
|出版日期: 2015年06月18日||內容資訊: 英文 20 Pages||
Trastuzumab是妨礙HER2/neu受體的單株抗體，主要是用作特定乳癌的治療。Trastuzumab在治療HER2陽性轉移性乳癌上有莫大影響。中國由於醫療環境的限制及知識不足，每年接受乳腺疾病檢查的女性為10％以下。為此，初期階段發現的乳癌，美國是80％，但中國僅為20％。在中國的醫院市場中，Shanghai Roche 與GENENTECHT佔Trastuzumab的市場佔有率。在2005-2014年之間，醫院的Trastuzumab的市場規模年複合成長率達到52.9％。
Monoclonal antibody, an epochal drug variety, plays an important role in the upgrading process of treatments for tumor and autoimmune disease, and has become a mainstream in the global market of targeting therapeutic agents. The manufacturers of antibody mainly concentrate in the hands of such drug giants as Roche, Amgen, Johnson & Johnson, Abbott, Novartis and Merck, among which Roche's Genetech boasts of the largest amount of monoclonal antibody varieties.
Developed by Genentech, trastuzumab was approved by FDA to be used in clinic in Sep. 1998 under the trade name of Herceptin, a major product of Roche. In 2013, the sales value of trastuzumab was USD 6.56 billion around the world.
After entering China in 2002 for the treatment of HER2 metastatic breast cancer, trastuzumab develops fast with annual sales value rising from less than CNY 20 million in 2005 to CNY 577 million in 2014 and CAGR during this period reaching up to 52.9%. Currently, trastuzumab in the Chinese market are monopolized by the subsidiary companies of Roche such as Genentech and Shanghai Roche Pharmaceutical Co., Ltd who has the largest market share of 80.60% with sales value in 2014 reaching up to CNY 465 million.
Due to its low toxicity and obvious therapeutic effects, trastuzumab can prolong patients' lives and improve the life quality of patients with advanced cancer, thus becoming the major driving force behind the growth of tumor monoclonal antibody market. The market size of trastuzumab in China is expected to keep expanding in the next few years.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report: